Rhythm Pharmaceuticals tech chief sells 45,921 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rhythm Pharmaceuticals, Inc. (RYTM) Chief Technical Officer Joseph Shulman exercised options for 40,467 common shares on November 18, 2026, at exercise prices of $6.80, $27.35, $49.23 and $56.69. He also sold 45,921 shares at a weighted-average price of $119.9049 per share; the sales were made at prices ranging from $119.75 to $120.36. The exercises and sale were under a Rule 10b5-1 trading plan adopted December 15, 2025.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) F1, F3 | 1,961 | $0.00 | $0.00 |
| Exercise | Stock Options (Right to Buy) F1, F4 | 4,188 | $0.00 | $0.00 |
| Exercise | Stock Options (Right to Buy) F1, F5 | 24,944 | $0.00 | $0.00 |
| Exercise | Stock Options (Right to Buy) F1, F6 | 9,374 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,961 | $6.80 | $13K |
| Exercise | Common Stock F1 | 4,188 | $27.35 | $115K |
| Exercise | Common Stock F1 | 24,944 | $49.23 | $1.23M |
| Exercise | Common Stock F1 | 9,374 | $56.69 | $531K |
| Sale | Common Stock F1, F2 | 45,921 | $119.9049 | $5.51M |
Footnotes (6)
- F1. The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
- F2. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $119.75 to $120.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- F4. The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- F5. The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- F6. The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
substantially equal installments technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.